The human microbiome refers to the ecosystem of microorganisms such as fungi, bacteria and viruses that live symbiotically in various areas of the human body including the gastrointestinal tract, respiratory tract, skin, and urogenital tract. Microbiome-based products aim to improve human health by restoring microbial balance and diversity. Products in the human microbiome market include probiotic food and beverage products, prebiotics, medical food, diagnostic tools, and drugs. Rising consumer awareness about the link between microbiome and various diseases including obesity, diabetes, and cancer has boosted the demand for probiotic food and drinks containing live microbial strains.
The global human microbiome market is estimated to be valued at US$ 4248.55 Mn in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
Rising interest in probiotic food and beverages driven by their ability to improve gut health has emerged as a key driver for the human microbiome market as highlighted in the heading. Probiotic foods containing bacterial strains such as Bifidobacterium and Lactobacillus are becoming increasingly popular among health-conscious consumers. Moreover, marketing claims by probiotic product manufacturers regarding weight management and digestion benefits are further fueling their demand. Another major factor propelling the market growth includes growing adoption of microbiome therapeutics for treating chronic diseases. Various clinical studies have demonstrated therapeutic potential of microbiome-based products for managing metabolic disorders, cancer, and neurological conditions, paving way for new drug launches. However, lack of standards for testing efficacy of probiotic products limits their widespread adoption. Development of these regulatory standards is expected to create new opportunities for product innovation in the coming years.
Segment Analysis
The global human microbiome market can be segmented based on product, disease indication, application and end user. Based on product type, the market is segmented into probiotics, prebiotics, diagnostic tests, drugs and other products. Among these, the probiotics segment dominates the market and accounts for the largest revenue share owing to increasing adoption of probiotic supplements for maintaining good gut health and immunity. Based on disease indication, the market covers diarrhea, obesity, cancer, COVID-19, cardiovascular diseases and others. The diarrhea segment captures a major market share due to growing use of probiotics as an effective treatment option for diarrhea.
PEST Analysis
Political: The market is positively impacted by supportive government policies and regulations favoring research funding in microbiome science. Various regions have implemented favorable reimbursement policies for advanced microbiome-based therapies and diagnostic tests.
Economic: The growing economic burden of lifestyle diseases and rising healthcare expenditure on treatments is fueling demand for cost-effective microbiome-based therapies. Additionally, investments by industry players for R&D of novel microbiome-based drugs and products are propelling market growth.
Social: Increasing health awareness among consumers regarding gut health and overall well-being is driving the adoption of probiotic supplements and microbiome-based treatments. Also, social media influence and marketing campaigns by brands are helping create awareness about human microbiome and its role in human health.
Technological: Significant advancements in omics technologies such as genomics, proteomics and metabolomics are supporting discoveries in human microbiome science. Also, developments in high-throughput sequencing platforms, bioinformatics and cell culture techniques are facilitating drug research and development activities in this field.
Key Takeaways
The Global Human Microbiome Market Growth is expected to witness high over the forecast period. The global human microbiome market is estimated to be valued at US$ 4248.55 Mn in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023 to 2030.
Regionally, North America captures the major market share of over 40% owing to strong government funding to research institutes for conducting clinical trials of microbiome-based therapies. Factors such as presence of highly advanced healthcare infrastructure and growing adoption of probiotic supplements are fueling the North America market.
Key players operating in the human microbiome market are Diageo plc, Pernod-Ricard SA, Constellation Brands Inc. Key players are focusing on new product launches, collaborations and partnerships with research institutes for drug development. For instance, in 2021 Diageo plc partnered with several research institutes including University of California San Diego to research effects of alcohol consumption on human gut microbiota.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it